Instituto Universitario de Investigación en Neuroquímica
Centro/Instituto
![Foto de Instituto Universitario de Investigación en Neuroquímica](/img/uploaded/210288F0EBF11B5B400384EE1F7A6332.jpg)
![Foto de Instituto Maimónides de Investigación Biomédica de Córdoba](/img/noimage_org.png)
Instituto Maimónides de Investigación Biomédica de Córdoba
Córdoba, EspañaPublicaciones en colaboración con investigadores/as de Instituto Maimónides de Investigación Biomédica de Córdoba (9)
2023
2021
-
(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice
Pharmacological Research, Vol. 169
-
Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease
Molecules, Vol. 26, Núm. 11
-
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Molecular and Cellular Neuroscience, Vol. 110
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
2019
-
Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease
Molecules, Vol. 24, Núm. 15
-
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
Translational Neurodegeneration, Vol. 8, Núm. 1
2018
-
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor
Journal of Neuroinflammation, Vol. 15, Núm. 1
-
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Biochemical Pharmacology, Vol. 157, pp. 217-226